These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2499297)

  • 1. Valpromide is a poor inhibitor of the cytosolic epoxide hydrolase.
    Pacifici GM; Temellini A; Giuliani L; Rane A; Thomas H; Oesch F
    Arch Toxicol; 1989; 63(2):157-9. PubMed ID: 2499297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation.
    Kerr BM; Rettie AE; Eddy AC; Loiseau P; Guyot M; Wilensky AJ; Levy RH
    Clin Pharmacol Ther; 1989 Jul; 46(1):82-93. PubMed ID: 2501059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valpromide inhibits human epoxide hydrolase.
    Pacifici GM; Franchi M; Bencini C; Rane A
    Br J Clin Pharmacol; 1986 Sep; 22(3):269-74. PubMed ID: 3094569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valpromide but not sodium hydrogen divalproate inhibits epoxide hydrolase in human liver.
    Pacifici GM; Rane A
    Pharmacol Toxicol; 1987 Mar; 60(3):237-8. PubMed ID: 3108874
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytosolic epoxide hydrolase in humans: development and tissue distribution.
    Pacifici GM; Temellini A; Giuliani L; Rane A; Thomas H; Oesch F
    Arch Toxicol; 1988; 62(4):254-7. PubMed ID: 3240091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous expression of human microsomal epoxide hydrolase in Saccharomyces cerevisiae. Study of the valpromide-carbamazepine epoxide interaction.
    Eugster HP; Sengstag C; Hinnen A; Meyer UA; Würgler FE
    Biochem Pharmacol; 1991 Sep; 42(7):1367-72. PubMed ID: 1930259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid.
    Spiegelstein O; Kroetz DL; Levy RH; Yagen B; Hurst SI; Levi M; Haj-Yehia A; Bialer M
    Pharm Res; 2000 Feb; 17(2):216-21. PubMed ID: 10751038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple epoxide hydrolases in human lung.
    Guenthner TM; Karnezis TA
    Drug Metab Dispos; 1986; 14(2):208-13. PubMed ID: 2870896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human liver cytosolic epoxide hydrolases.
    Schladt L; Thomas H; Hartmann R; Oesch F
    Eur J Biochem; 1988 Oct; 176(3):715-23. PubMed ID: 3169021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of cytosolic epoxide hydrolase activity in vitro by compounds that inhibit catalase.
    Guenthner TM; Hjelle JT; Whalen R
    J Biochem Toxicol; 1989; 4(4):241-9. PubMed ID: 2634095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of crude and affinity purified cytosolic epoxide hydrolases from hepatic tissue of control and clofibrate-fed mice.
    Hammock BD; Prestwich GD; Loury DN; Cheung PY; Eng WS; Park SK; Moody DE; Silva MH; Wixtrom RN
    Arch Biochem Biophys; 1986 Jan; 244(1):292-309. PubMed ID: 3947062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of epoxide hydrolases and glutathione S-transferases by 2-, 3-, and 4-substituted derivatives of 4'-phenylchalcone and its oxide.
    Miyamoto T; Silva M; Hammock BD
    Arch Biochem Biophys; 1987 Apr; 254(1):203-13. PubMed ID: 3579298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarities between catalase and cytosolic epoxide hydrolase.
    Guenthner TM; Qato M; Whalen R; Glomb S
    Drug Metab Rev; 1989; 20(2-4):733-48. PubMed ID: 2806078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification of human liver cytosolic epoxide hydrolase and comparison to the microsomal enzyme.
    Wang P; Meijer J; Guengerich FP
    Biochemistry; 1982 Nov; 21(23):5769-76. PubMed ID: 6185139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of cytosolic epoxide hydrolase purified from the liver of untreated and clofibrate-treated mice. Characterization of optimal assay conditions, substrate specificity and effects of modulators on the catalytic activity.
    Meijer J; Depierre JW
    Eur J Biochem; 1985 Jul; 150(1):7-16. PubMed ID: 4018080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and characterization of rat-liver cytosolic epoxide hydrolase.
    Schladt L; Hartmann R; Wörner W; Thomas H; Oesch F
    Eur J Biochem; 1988 Sep; 176(1):31-7. PubMed ID: 3046942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of epoxide hydrolase from human, monkey, bovine, rabbit and murine liver by trans-3-phenylglycidols.
    Dietze EC; Casas J; Kuwano E; Hammock BD
    Comp Biochem Physiol B; 1993 Feb; 104(2):309-14. PubMed ID: 8462281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.
    Pisani F; Fazio A; Oteri G; Spina E; Perucca E; Bertilsson L
    Br J Clin Pharmacol; 1988 May; 25(5):611-3. PubMed ID: 3136790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential substrate selectivity of murine hepatic cytosolic and microsomal epoxide hydrolases.
    Hammock BD; Hasagawa LS
    Biochem Pharmacol; 1983 Apr; 32(7):1155-64. PubMed ID: 6847708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organ distribution of epoxide hydrolases in cytosolic and microsomal fractions of normal and nafenopin-treated male DBA/2 mice.
    Waechter F; Bentley P; Bieri F; Muakkassah-Kelly S; Stäubli W; Villermain M
    Biochem Pharmacol; 1988 Oct; 37(20):3897-903. PubMed ID: 3190736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.